ProPhase Labs Shareholders Approve Strategic Expansion, Including Increase In Authorized Shares To 1B

ProPhase Labs Stockholders Deliver Strong Mandate at Special Meeting

UNIONDALE, NY, Sept. 12, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next generation biotech, genomics and consumer products company, today announced that stockholders delivered a strong mandate at the Company's September 9, 2025 Special Meeting, approving all proposals on the agenda. With each proposal receiving more than 75% support, ProPhase received clear authorization to move forward with its strategic initiatives, including a significant increase in authorized shares to 1 billion.

This success follows the re-election of the Board at the June annual meeting by in excess of 90% in favor of each director.

Final voting results will be reported on a Current Report on Form 8-K filed with the Securities and Exchange Commission.

The Company anticipates that it will be updating stockholders in the near future regarding positive developments in the Crown Medical Collections initiative to net up to $50 million in Covid accounts receivables as well as positive developments toward the commercialization of its BE-Smart Esophageal Cancer Test.